Blood serum alpha fetoprotein enhancer binding protein, a tumor suppressor, decreases in chronic HBV hepatitis patients as hepatocellular cancer appears

Article type: Research Article

Authors: Riggins, James N.^; | Corey, William | Fonteh, Alfred N. | Harrington, Michael G.

Affiliations: Molecular Neurology Program, Huntington Medical Research Institutes, Pasadena, CA, USA | HMRI Liver Center, Pasadena, CA, USA

Note: [] Corresponding author: Michael G. Harrington, Huntington Medical Research Institutes, 99 North El Molino Avenue, Pasadena, CA 91101, USA. Tel.: +1 626 795 4343; Fax: +1 626 795 5774; E-mail: mghworks@hmri.org

Abstract: Chronic hepatitis increases the risk of hepatocellular carcinoma (HCC). To test whether circulating proteins reflect hepatic carcinogenesis, sera from patients and controls were albumin depleted, enriched for glycoproteins, digested with trypsin, and subjected to reverse phase chromatography and tandem mass spectrometry. Alpha-fetoprotein enhancer binding protein (AFPebp), a tumor suppressor, was repeatedly identified in sera from chronic HBV hepatitis patients. We independently identified and quantified AFPebp with a deuterated, phenylisocyanate-labeled synthetic peptide standard. Elevated AFPebp levels in sera from chronic HBV hepatitis patients decreased as cancer developed. These data suggest that rising AFPebp levels in chronic HBV hepatitis may be protective, while falling levels may contribute to HCC development.

Keywords: Alpha-fetoprotein, alpha-fetoprotein enhancer binding protein, tumor suppressor, hepatitis B virus, hepatitis C virus, hepatocellular carcinoma, liquid chromatography, tandem mass spectrometry, phenylisocyanate, deuterium

DOI: 10.3233/DMA-2010-0692

Journal: Disease Markers, vol. 28, no. 3, pp. 125-135, 2010